|
| |
BioJournal - URCH Publishing
To view descriptions and
buy online -
click
here!
 |
For many years generic companies were the poor relations of the
pharmaceutical industry, with modest growth rates and little or no
transnational business operations. As generics companies have grown, often
by acquisition, they have generally developed as international businesses. |
|
|
"The global pharmaceutical market grew to US$643 billion in 2006,
growing at a compound annual growth rate (CAGR) of 10.0% between 1999 and
2006. However, year-on-year growth slowed to 6.8% in 2006, largely as a
result of increased competition from generic products and the effects of
continued healthcare cost containment across major markets." |
|
|
The global cardiovascular market is forecast to expand to US$116.3 billion
in 2010, equivalent to a CAGR of 5.3% over the next five years. The
slow-down in cardiovascular market growth between 2003 and 2005 is forecast
to continue through to 2010. While continued changes in demographics and
lifestyle will continue to drive cardiovascular sales forward, growth rates
will be limited by continued patent expiries for major products and a dearth
of novel therapies being introduced.Cardiovascular Pharmaceutical Market
Trends, 2007 to 2010 - Key market forecasts and growth opportunities
provides an in-depth analysis of the growing market for pharmaceutical
treatments for cardiovascular disorders including:
- Coronary heart disease- Cerebrovascular disease
- Peripheral arterial disease- Rheumatic heart disease
- Congenital heart disease- Deep vein thrombosis and pulmonary embolism
This comprehensive report, from URCH Publishing, delivers market forecasts
and overviews to help inform you in your pharmaceutical business
decision-making. |
|
|
The global market for drugs treating Central Nervous System (CNS)
disorders has grown rapidly in recent years to reach US$55.5 billion in
2005, a year-on-year increase of 6.6%. Between 2003 and 2005, global CNS
sales increased by 19% and accounted for 9.2% of total global pharmaceutical
sales in 2005. Annual global CNS sales growth slowed from 11.5% in 2004 to
6.6% in 2005 as a result of generic competition for leading anti-depressant
and epilepsy therapies. |
|
|
The Handbook of Pharmaceutical Additives, 3rd Edition describes more
than 5,300 trade name products and 4,000 generic chemicals and materials,
available from worldwide manufacturers, that function as pharmaceutical
additives. |
|
|
“The period 2007 to 2011 will see the expiration of patent protection
for 52 major drugs in the United States, an average of ten a year. With 2005
seeing a decline in the number of NCEs approved down to 18 from 23 in 2004,
there is clear evidence that the loss of revenue from patent protected drugs
will impact upon the growth of the industry when so few new drugs are
reaching the market.“ |
|
|
The global cancer market has just seen a period of rapid growth. Between
2003 and 2005, global sales for cancer treating drugs increased by 40% and
now account for more than eight percent of total global pharmaceutical
sales. Although growth rates for this market will slow due to generic
competition the market is predicted to expand to $85.3 billion by 2010
equivalent to CAGR of 11.1% |
|
|
Major Pharmaceutical Markets of the Middle East is a comprehensive
report providing extensive coverage of one of the strongest emerging
markets. Through quality analysis and forecasts, this unique report will
allow you to identify market trends and growth potential opportunities.
The report provides the necessary background information for a firm to
operate in the region. |
|
|
"it must be acknowledged that few pharmaceutical manufacturers, let
along biotech companies are equipped to meet these new health technology
assessment guidelines" This essential report will help you:
Prepare a global dossier to ensure successful formulary listingUnderstand
formulary submission guidelines in Australia, UK and USA
Respond to emerging evidentiary and analytical standards
Structure your organisation to make a convincing case to the regulators |
 |
BioGenerics is an umbrella term used to define the market for
bioequivalent products based on the same biological substance used in
off-patent biologics. The BioGeneric market is set to develop slowly in the
major pharmaceutical markets, as a result of regulatory hurdles and
continued protectionism from patented biopharmaceutical marketers. Once the
market does begin to evolve, the biogeneric companies entering the market
early will derive significant value. |
 |
National pharmaceutical pricing and reimbursement is a complex and
ever-changing area. In a rapidly globalising market it is essential that
executives are briefed on the regulatory systems that determine the way in
which your company operates and sells its products. The Guide to
Pharmaceutical Pricing and Reimbursement Systems: Western Europe is a
straightforward guide to the pricing and reimbursement mechanisms in the
major European markets. |
| |
|
